Global pharmaceutical leader Lupin Limited (Lupin) today announced the release of Darunavir tablets 600 mg and 800 mg as a generic alternative to Janssen Products, LP’s Prezista® Tablets. According to IQVIA MAT March 2023, Darunavir Tablets, 600 mg and 800 mg, had expected annual sales of USD 308 million in the United States.

More About Darunavir Tablets

Darunavir is an antiretroviral medication used in the treatment of HIV-1 infection. It belongs to a class of drugs called protease inhibitors. Darunavir works by inhibiting the protease enzyme, which is necessary for the replication of the HIV virus.

Darunavir is available in tablet form, with two commonly used strengths: 600 mg and 800 mg. These tablets are typically used in combination with other antiretroviral drugs to form a complete regimen for HIV treatment. The specific dosage and combination of medications will depend on various factors, such as the individual’s medical history, viral load, and treatment response.

The 600 mg strength tablets are often used in combination with a low dose of ritonavir, another protease inhibitor. Ritonavir is used to enhance the levels of darunavir in the blood, allowing for more effective treatment. This combination is referred to as darunavir/ritonavir.

The 800 mg strength tablets of darunavir are newer and may offer some advantages over the 600 mg formulation. The 800 mg tablets can be taken without ritonavir, as they contain a novel pharmacokinetic enhancer called cobicistat. Cobicistat acts similar to ritonavir, boosting the levels of darunavir in the blood. This combination is referred to as darunavir/cobicistat.

It’s important to note that the use of darunavir and the specific dosage should be determined by a healthcare professional experienced in the treatment of HIV. They will consider various factors and tailor the treatment regimen to the individual’s needs. Additionally, darunavir is not a cure for HIV, but it can help control the virus and improve the individual’s immune function when used as part of a comprehensive antiretroviral therapy plan.

More About HIV-1 infection

HIV-1 (Human Immunodeficiency Virus-1) is a retrovirus that attacks the immune system, specifically targeting CD4+ T cells, which play a crucial role in the body’s defense against infections. When HIV-1 infects these cells, it replicates and gradually weakens the immune system, making the body more susceptible to various infections and diseases.

Transmission of HIV-1 primarily occurs through the exchange of certain bodily fluids, including blood, semen, vaginal fluids, and breast milk. Common routes of transmission include unprotected sexual intercourse, sharing needles or syringes contaminated with the virus, and transmission from an infected mother to her child during childbirth or breastfeeding. HIV-1 is not transmitted through casual contact, such as hugging, shaking hands, or sharing utensils.

After initial infection, individuals may experience flu-like symptoms, such as fever, fatigue, sore throat, and swollen lymph nodes. However, many people with HIV-1 infection may not exhibit any symptoms during the initial stages, leading to delayed diagnosis. Over time, if left untreated, HIV-1 infection progresses to a more advanced stage known as acquired immunodeficiency syndrome (AIDS), characterized by severe immune system damage and an increased risk of opportunistic infections and certain cancers.

The diagnosis of HIV-1 infection is typically confirmed through blood tests that detect the presence of antibodies or viral genetic material (RNA or DNA). Early detection is crucial for timely intervention and management.

Antiretroviral therapy (ART) is the cornerstone of HIV-1 treatment. ART involves the use of a combination of antiretroviral drugs that suppress the replication of the virus, allowing the immune system to recover and function effectively. This treatment approach has significantly transformed HIV-1 infection into a manageable chronic condition for many individuals, reducing illness, prolonging life expectancy, and reducing the risk of transmission.

Prevention of HIV-1 infection involves various strategies, including practicing safe sex by using condoms, getting tested for HIV-1 and other sexually transmitted infections, avoiding needle sharing, and utilizing pre-exposure prophylaxis (PrEP) for individuals at high risk of contracting HIV-1.

It’s important to note that while significant progress has been made in the treatment and prevention of HIV-1 infection, it remains a global health challenge. Continued efforts in education, awareness, access to healthcare, and research are crucial to further improve the management and ultimately find a cure for this complex disease.

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.9% of its revenue in research and development in FY23.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.

About Publisher

IR Research Publication is Publisher, Editorial, and Profile Building Service Provider. It Covers the Publication of Multiple Reputed Journals in the field of Biological, Medical, Pharmaceutical, and Life Sciences. IR Research Publication provides news on CDSCO decisions and FDA decisions, pharmaceutical industries, generic drugs, patents, and other pharma news.
For more details Click here

For more Pharma related updates Click here